- Home
- AKA vs BDTX Comparison
AKA vs BDTX Comparison
Compare AKA & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKA | BDTX |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.4M | 104.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AKA | BDTX |
|---|---|---|
| Price | $10.60 | $1.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $19.75 | $10.00 |
| AVG Volume (30 Days) | 866.0 | ★ 610.9K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,208,000.00 | N/A |
| Revenue This Year | $4.92 | N/A |
| Revenue Next Year | $5.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.44 | N/A |
| 52 Week Low | $8.42 | $1.60 |
| 52 Week High | $15.38 | $4.94 |
Technical Indicators
Market Signals| Indicator | AKA | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.39 | 47.14 |
| Support Level | $10.23 | $1.79 |
| Resistance Level | $11.43 | $1.93 |
| Average True Range (ATR) | 0.35 | 0.09 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 33.82 | 61.11 |
Price Performance
Historical ComparisonAbout AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.